Cell News and Research

RSS

Aduro BioTech announces issuance of two important patents

Aduro BioTech, a clinical-stage immunotherapy company, announced today the issuance of two important patents, the formation of a distinguished scientific advisory board, the addition of key members to its Board of Directors, and the reporting of preliminary top line long-term survival data from a Phase 1 clinical trial with 2 year follow-up.

15 Jul 2010

Cervical cancer vaccine could reduce number of cases from 3,000 to less than 700 every year

The cervical cancer vaccine could prevent even more cases of the disease in England than previously thought, UK scientists have found.

15 Jul 2010

Long-term exposure of arsenic may increase risk for lung cancer

To determine how arsenic increases the risk of lung cancer and to identify potential treatments, a Michigan State University researcher will use $1.7 million in federal funding during the next five years to examine why certain genes disrupt cells, leading to the disease.

15 Jul 2010

Kidney Cancer Canada applauds Ontario for granting coverage for RCC therapy TORISEL

Ontario has taken a major step forward in access to treatment for patients in the province with advanced kidney cancer by granting coverage for TORISELTM (temsirolimus), for advanced renal cell carcinoma (RCC) with poor prognostic features.

15 Jul 2010

MD Buyline identifies top emerging technologies with highest impact

This release will explain how these important technologies encourage high utilization rates across multiple service lines, bringing value to hospitals. Reimbursement changes and hospital structure enable technology purchases to generate a sequence of changes throughout service lines and dramatically impact the bottom line.

15 Jul 2010

New Cystex Liquid Cranberry Complex with Proantinox reduces incidence of UTIs in women: Study

A new study being published in the journal Urology shows that Proantinox, a proprietary cranberry-based blend used successfully in hospitals and long-term care facilities as UTI-Stat, and now available directly to consumers as new Cystex Liquid Cranberry Complex with Proantinox, is safe and effective in significantly reducing the incidence of UTIs in women at risk for recurring infections.

15 Jul 2010

New research focuses on calcium channels in lysosome membrane

In cells, as in cities, disposing of garbage and recycling anything that can be reused is an essential service. In both city and cell, health problems can arise when the process breaks down.

15 Jul 2010

Two patents issued for GlycoMimetics lead drug candidate, related compounds

GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that the U. S. Patent and Trademark Office has issued two patents covering the company's lead drug candidate and related compounds. One patent, US number 7,728,117, specifically covers GMI-1070, the Company's drug candidate now in clinical trials of patients with vaso-occlusive crisis of sickle cell disease. The second patent, US number 7,741,312, contains claims covering a family of molecules that includes and extends beyond GMI-1070.

15 Jul 2010

Keck School of Medicine receives grant for research on biomarker impact on breast cancer screening

Researchers at the Keck School of Medicine of the University of Southern California (USC) will test whether a set of blood-based biomarkers can assist mammography in the early detection of breast cancer with a $180,000 grant announced today from Susan G. Komen for the Cure®. The grant will fund research into whether specific biomarkers, or minute substances in the blood, can effectively distinguish breast cancer patients from their healthy counterparts and whether an inexpensive, less invasive screening strategy can be developed based on this approach.

15 Jul 2010

JNK protein controls cell cycle, new study reveals

Put simply, a tumor is the result of out-of-control cell growth. To assure that the cell cycle - the cell's process of duplicating itself to make more cells - goes smoothly, a large network of proteins tells other proteins what to do and when to do it. When any of these layers of protein regulation fail, cell growth can get out of hand. A new study led by Ze'ev Ronai, Ph.D., associate director of Sanford-Burnham's National Cancer Institute-designated Cancer Center, reveals a new player in cell cycle control.

15 Jul 2010

Evotec to acquire DeveloGen

Evotec AG today announced the signing of a definitive agreement to acquire DeveloGen, a biopharmaceutical company engaged in the discovery of novel therapeutic approaches for the treatment of metabolic and endocrine disorders, for up to €14m in shares plus performance-related deferred payments (earn-out).

15 Jul 2010

KRX-0401 receives Orphan Drug designation from FDA for treatment of neuroblastoma

Keryx Biopharmaceuticals, Inc. today announced that KRX-0401 (perifosine) has received Orphan Drug designation from the U.S. Food and Drug Administration for the treatment of neuroblastoma, a cancer of the nervous system affecting mostly children and infants for which there are no FDA approved therapies.

15 Jul 2010

SWCRF/Emerald Foundation Global Collaborative Grant to fund critical cancer research

The leukemia stem cell-the root cause of all acute leukemias- represents a small population of cells in patients that are difficult to eliminate with standard treatments available today. Though current chemotherapy can produce temporary remission in leukemia survivors, they remain at risk of experiencing a recurrence and dying from the disease.

15 Jul 2010

CardioGenics Holdings' subsidiary signs second product agreement with Merck Chimie

CardioGenics Holdings Inc., developer of the ultra-sensitive QL Care Point-Of-Care analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced that the Company's subsidiary, CardioGenics Inc., has entered into an agreement with Merck Chimie S.A.S. to adopt its proprietary biological-linking technology to Merck-supplied magnetic beads designed to increase yields in antibody manufacturing.

15 Jul 2010

Absorption Systems' GLP facility receives full accreditation from AAALAC

Absorption Systems, a leader in testing drugs for ADMET, announced today that its GLP facility in San Diego, Calif., for preclinical testing of drugs, biologics and medical devices received full accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care International.

15 Jul 2010

Aeterna Zentaris' partner Keryx receives FDA orphan-drug designation for perifosine in neuroblastoma

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, Inc., has been granted orphan-drug designation by the U.S. Food and Drug Administration for perifosine, Aeterna Zentaris' novel, potentially first-in-class, oral Akt inhibitor, for the treatment of neuroblastoma.

15 Jul 2010

Hendra virus treatment to be ready in a few months

Of the dozen people who were exposed to a horse infected with the Hendra virus, 11 have been cleared of the infection by repeated tests on Queensland's Sunshine Coast. These 12 people had first come into contact with the infected horse at Tewantin in May and have since then been subjected to testing to rule out infection with the deadly virus. It is expected that the 12th person will also be cleared soon. Quarantine restrictions were also lifted last month.

14 Jul 2010

Aastrom commences extension study for control patients from Phase 2 IMPACT-DCM clinical trial

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced the initiation of an extension study for control patients from the company's ongoing open-label Phase 2 IMPACT-DCM clinical trial in patients with dilated cardiomyopathy (DCM).

14 Jul 2010

NIAID awards ATCC multimillion dollar MID-BRR contract

ATCC, the premier biological materials resource, services, and standards organization, has been awarded the National Institute of Allergy and Infectious Diseases, Microbiology and Infectious Diseases Biological Resource Repository ("MID-BRR") contract, ATCC announced today. The current value of the contract is $14,615,598 with the ultimate value of $115,733,409 over 7 years with an annual renewal.

14 Jul 2010

Maven Semantic announces updates to database of Toxicology researchers

Maven Semantic announces updates to their Toxicology database.

14 Jul 2010

Cell News and Research

Aduro BioTech announces issuance of two important patents

Cervical cancer vaccine could reduce number of cases from 3,000 to less than 700 every year

Long-term exposure of arsenic may increase risk for lung cancer

Kidney Cancer Canada applauds Ontario for granting coverage for RCC therapy TORISEL

MD Buyline identifies top emerging technologies with highest impact

New Cystex Liquid Cranberry Complex with Proantinox reduces incidence of UTIs in women: Study

New research focuses on calcium channels in lysosome membrane

Two patents issued for GlycoMimetics lead drug candidate, related compounds

Keck School of Medicine receives grant for research on biomarker impact on breast cancer screening

JNK protein controls cell cycle, new study reveals

Evotec to acquire DeveloGen

KRX-0401 receives Orphan Drug designation from FDA for treatment of neuroblastoma

SWCRF/Emerald Foundation Global Collaborative Grant to fund critical cancer research

CardioGenics Holdings' subsidiary signs second product agreement with Merck Chimie

Absorption Systems' GLP facility receives full accreditation from AAALAC

Aeterna Zentaris' partner Keryx receives FDA orphan-drug designation for perifosine in neuroblastoma

Hendra virus treatment to be ready in a few months

Aastrom commences extension study for control patients from Phase 2 IMPACT-DCM clinical trial

NIAID awards ATCC multimillion dollar MID-BRR contract

Maven Semantic announces updates to database of Toxicology researchers

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News